Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Roos S G Sablerolles; Abraham Goorhuis; Corine H GeurtsvanKessel; Rory D de Vries; Anke L W Huckriede; Marion P G Koopmans; Melvin Lafeber; Douwe F Postma; Debbie van Baarle; Leo G Visser; Virgil A S H Dalm; Neeltje A Kootstra; Wim J R Rietdijk; P Hugo M van der Kuy

doi:10.3389/fimmu.2021.753319

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Roos S G Sablerolles, Abraham Goorhuis, Corine H GeurtsvanKessel, Rory D de Vries, Anke L W Huckriede, Marion P G Koopmans, Melvin Lafeber, Douwe F Postma, Debbie van Baarle, Leo G Visser, Virgil A S H Dalm, Neeltje A Kootstra, Wim J R Rietdijk, P Hugo M van der Kuy^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

143 Downloads (Pure)

Original language	English
Article number	753319
Number of pages	4
Journal	Frontiers in Immunology
Volume	12
DOIs	https://doi.org/10.3389/fimmu.2021.753319
Publication status	Published - 24-Sep-2021

Keywords

SARS-CoV-2
COVID-19
Homologous vaccination regimen
Heterologous vaccine regimen
randomized clinical trial
Ad26.Cov2.S
BNT162.b2
mRNA1273 & nbsp;
REACTOGENICITY

Access to Document

10.3389/fimmu.2021.753319Licence: CC BY

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination RegimensFinal publisher's version, 1.09 MBLicence: CC BY

Handle.net

Persistent link

Cite this

Sablerolles, R. S. G., Goorhuis, A., GeurtsvanKessel, C. H., de Vries, R. D., Huckriede, A. L. W., Koopmans, M. P. G., Lafeber, M., Postma, D. F., van Baarle, D., Visser, L. G., Dalm, V. A. S. H., Kootstra, N. A., Rietdijk, W. J. R., & van der Kuy, P. H. M. (2021). Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol. Frontiers in Immunology, 12, [753319]. https://doi.org/10.3389/fimmu.2021.753319

@article{c11895e7a93f421887894f84a8d133cc,

title = "Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol",

keywords = "SARS-CoV-2, COVID-19, Homologous vaccination regimen, Heterologous vaccine regimen, randomized clinical trial, Ad26.Cov2.S, BNT162.b2, mRNA1273 & nbsp;, REACTOGENICITY",

author = "Sablerolles, {Roos S G} and Abraham Goorhuis and GeurtsvanKessel, {Corine H} and {de Vries}, {Rory D} and Huckriede, {Anke L W} and Koopmans, {Marion P G} and Melvin Lafeber and Postma, {Douwe F} and {van Baarle}, Debbie and Visser, {Leo G} and Dalm, {Virgil A S H} and Kootstra, {Neeltje A} and Rietdijk, {Wim J R} and {van der Kuy}, {P Hugo M}",

year = "2021",

month = sep,

day = "24",

doi = "10.3389/fimmu.2021.753319",

language = "English",

volume = "12",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

Sablerolles, RSG, Goorhuis, A, GeurtsvanKessel, CH, de Vries, RD, Huckriede, ALW, Koopmans, MPG, Lafeber, M, Postma, DF , van Baarle, D, Visser, LG, Dalm, VASH, Kootstra, NA, Rietdijk, WJR & van der Kuy, PHM 2021, 'Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol', Frontiers in Immunology, vol. 12, 753319. https://doi.org/10.3389/fimmu.2021.753319

TY - JOUR

T1 - Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens

T2 - The SWITCH Trial Protocol

AU - Sablerolles, Roos S G

AU - Goorhuis, Abraham

AU - GeurtsvanKessel, Corine H

AU - de Vries, Rory D

AU - Huckriede, Anke L W

AU - Koopmans, Marion P G

AU - Lafeber, Melvin

AU - Postma, Douwe F

AU - van Baarle, Debbie

AU - Visser, Leo G

AU - Dalm, Virgil A S H

AU - Kootstra, Neeltje A

AU - Rietdijk, Wim J R

AU - van der Kuy, P Hugo M

PY - 2021/9/24

Y1 - 2021/9/24

KW - SARS-CoV-2

KW - COVID-19

KW - Homologous vaccination regimen

KW - Heterologous vaccine regimen

KW - randomized clinical trial

KW - Ad26.Cov2.S

KW - BNT162.b2

KW - mRNA1273 & nbsp;

KW - REACTOGENICITY

U2 - 10.3389/fimmu.2021.753319

DO - 10.3389/fimmu.2021.753319

M3 - Article

C2 - 34691071

VL - 12

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 753319

ER -